Nature sub-journal: Sun Yat-sen University discovers the first method to detect ABE genome-wide off-target effects
The adenine base editor (ABE) can catalyze A-T to G-C conversion and is an important tool in the gene editing toolbox. On January 8, 2019, a research team composed of Sun Yat-sen University, Guangzhou Medical University, the Chinese Academy of Medical Sciences and some American scholars published a research paper in Nature Communications titled "Genome-wide profiling of adenine base editor specificity by EndoV-seq". The corresponding authors are Professor Huang Junjiu and Professor Song Yangzhou of Sun Yat-sen University. The study demonstrated the first detection method capable of detecting genome-wide off-target effects of ABE, and revealed possible similarities and differences between ABE and the classical Cas9 nuclease.
The research team used their independently developed EndoV-seq platform to systematically evaluate the off-target deamination of ABE across the whole genome. EndoV-seq uses endonuclease V to cleave, in vitro, the inosine-containing DNA strands generated by ABE deamination of genomic DNA. The treated DNA is then subjected to whole-genome sequencing to identify off-target sites.
Among the 8 gRNAs tested with ABE by the researchers, 2-19 (average 8.0) off-target sites were found, significantly fewer than with the classical Cas9 nuclease (7-320, average 160.7). In vivo off-target deamination was further verified by deep sequencing of target sites.
In addition, the researchers demonstrated that six different ABE-gRNA complexes can be examined in a single EndoV-seq assay. This study demonstrated the first detection method for genome-wide off-target effects of ABE, and revealed possible similarities and differences between ABE and the classical Cas9 nuclease. Original link: https://www.nature.com/articles/s41467-018-07988-z. Source: WeChat official account iNature.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.